← All trials
NCT03530124
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2018
- Primary completion
- Oct 31, 2020
- Completion date
- Nov 14, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of North Carolina at Chapel HillCollaborator
- Centers for Disease Control and Prevention (CDC)Overall official - principal investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
- University of CincinnatiOverall official - principal investigator
- University of CincinnatiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.